Stockreport

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical tria [Read more]